Rejuran S – 1 x 1ml

Rejuran

Skin booster

Polynucleotide (PN) injectable for acne scars and skin regeneration

CE Marked medical device (scar Repair PN injectable) according to multiple distributor and wholesale listings.
Registered as a Class III medical device in certain regulatory jurisdictions (e.g. listed on the Australian Register of Therapeutic Goods as a dermal tissue reconstructive material).
Approved by the Korean Ministry of Food and Drug Safety (MFDS) and Singapore HSA for medical use (scar treatment indications).
Manufactured under medical device quality management systems by PharmaResearch Co., Ltd. in South Korea.

CE Marked medical device (scar Repair PN injectable) according to multiple distributor and wholesale listings.
Registered as a Class III medical device in certain regulatory jurisdictions (e.g. listed on the Australian Register of Therapeutic Goods as a dermal tissue reconstructive material).
Approved by the Korean Ministry of Food and Drug Safety (MFDS) and Singapore HSA for medical use (scar treatment indications).
Manufactured under medical device quality management systems by PharmaResearch Co., Ltd. in South Korea.

Polynucleotide (PN) injectable for acne scars and skin regeneration

Description

Rejuran S is a high-viscosity, polynucleotide (PN)–based injectable skin booster specifically formulated to treat atrophic acne scars, surgical scars, and other depressed skin defects. Containing highly purified salmon DNA–derived polynucleotides at 2% (20 mg/ml), this regenerative dermal filler stimulates fibroblasts, boosts collagen production, accelerates tissue repair, and improves overall skin texture and elasticity. Its denser, more localized gel consistency allows it to act both as a biostimulatory scar-repair agent and as a subtle filler, lifting sunken scars while promoting long-term dermal remodeling. It is intended for intradermal injection by trained medical professionals only.

Bnefits

Fills and lifts depressed acne and surgical scars for smoother skin texture.
Contains highly concentrated polynucleotides (PN) derived from salmon DNA to stimulate fibroblasts and collagen synthesis.
Promotes intensive skin regeneration and repair at the dermal level.
Improves overall skin quality, including firmness, elasticity, and resilience.
Refines enlarged pores and helps even out skin tone and texture in scarred areas.
High-viscosity gel stays localized in depressed scars for targeted, long-lasting effect.
Biocompatible and biodegradable formulation with very high reported biocompatibility.
Can be combined with other treatments such as lasers, microneedling, or Rejuran Healer for enhanced scar improvement.

Indications

Atrophic acne scars (e.g. boxcar, rolling, and certain ice-pick scars as clinically appropriate).
Depressed surgical scars.
Post-traumatic and post-inflammatory depressed scars.
Localized skin depressions and textural irregularities.
Improvement of skin quality in scarred areas, including texture, firmness, and pore appearance.

Composition

Polynucleotide (PN, polydeoxyribonucleotide sodium) 2% (20 mg/ml) derived from salmon DNA.
Buffered aqueous solution suitable for intradermal injection (exact buffer composition not publicly listed).
Some marketed presentations include lidocaine hydrochloride 0.3% as a local anaesthetic (check specific pack labelling).
Water for injections.

Formulation

High-viscosity, transparent injectable gel based on long-chain polynucleotides.
Regenerative dermal tissue stimulator and skin booster rather than a traditional volumising hyaluronic acid filler.
Acts as a localized biostimulant and subtle filler in depressed scar areas.
Sterile, pyrogen-controlled injectable medical device supplied in a pre-filled syringe.
Intended for intradermal or very superficial subcutaneous injection by qualified healthcare professionals.

Packaging

Box containing 1 pre-filled 1 ml syringe of Rejuran S.
Typically supplied with a fine injection needle (e.g. 30G, 8 mm; exact needle specification may vary by distributor).
Sterile blister packaging for syringe (and needle where supplied).
Instructions for use (IFU) / product leaflet.
Traceability labels for inclusion in patient records where provided.

Usage

For professional use only: treatment must be performed by a licensed and appropriately trained medical practitioner experienced with injectable biostimulators.
Cleanse and disinfect the treatment area thoroughly before injection; apply topical anaesthetic cream according to clinic protocol if needed.
Inject small amounts of Rejuran S intradermally or at the base of the scar using a fine needle (commonly around 30G), employing serial puncture or micro-droplet technique.
Place micro-deposits directly within and just beneath atrophic scars to lift depressions and stimulate scar remodeling.
Typical protocol involves 3–4 treatment sessions spaced approximately 3–4 weeks apart; the precise number of sessions and intervals should be individualized based on clinical assessment.
Maintenance sessions can be performed roughly every 6–12 months, or as needed, to sustain scar improvement and skin quality.
Avoid intravascular injection by using correct depth and angle; aspirate cautiously where appropriate and inject slowly with low pressure.
After treatment, mild massage may be applied if clinically appropriate to distribute product evenly in the scar area.
Advise patients to avoid makeup, intense exercise, saunas, sunbeds, and extreme temperatures for at least 24 hours or according to clinic protocol.
Follow the official instructions for use (IFU) and local regulatory guidance for complete details on indications, dosing, technique, and precautions.

Contraindications

Known hypersensitivity or allergy to polynucleotides, salmon-derived products, or any component of the formulation.
History of severe allergic reactions or anaphylaxis to injectable products.
Active skin infections, inflammation, or dermatologic disease (e.g. bacterial, viral such as herpes, or fungal) at or near the intended injection sites.
Autoimmune disease or immunocompromised state, unless the treating physician judges treatment appropriate after individual risk–benefit assessment.
Coagulation disorders or current use of anticoagulant or antiplatelet medications that significantly increase bleeding or bruising risk, unless carefully evaluated by a physician.
Pregnancy and breastfeeding (generally not recommended due to lack of sufficient safety data).
Patients under 18 years of age.
Previous permanent fillers or foreign bodies in the same area, where interaction risk exists, unless assessed and approved by an experienced practitioner.
Any general contraindication to injectable aesthetic procedures as determined by the treating healthcare professional.

Adverse Effects

Common transient injection-site reactions such as redness (erythema), mild swelling or oedema, tenderness, itching, or a feeling of tightness.
Minor pain or discomfort at the injection site, usually resolving within 24–48 hours.
Small papules or bumps at injection points that typically subside over a few days.
Bruising or small haematomas at injection sites.
Temporary skin sensitivity or mild irritation in treated areas.
Rare delayed inflammatory or hypersensitivity reactions, including prolonged redness, swelling, or induration, which may require medical management.
Infection at the injection site if aseptic technique is not strictly followed.
Very rare but serious complications associated with any injectable procedure, such as inadvertent intravascular injection leading to tissue ischaemia or necrosis, or embolic events; these require immediate emergency management by a suitably trained physician.
Any unexpected, persistent, or severe adverse event should be evaluated promptly and managed according to clinical best practice and official product guidance.

Storage Conditions

Store refrigerated at 2–8 °C in accordance with product labelling from aesthetic distributors.
Do not freeze.
Keep in the original packaging to protect from light and contamination until use.
Avoid exposure to direct sunlight and excessive heat.
Do not use after the expiry date stated on the packaging.
Use only if the syringe and packaging are intact and the solution appears clear and free from visible particles.
Single-use product: do not resterilize and do not reuse any opened or partially used syringe.

Duration

Scar and texture improvements are typically progressive over several weeks and can be maintained for around 9\u201312 months or longer after a full course of 3\u20134 sessions, depending on scar severity, individual healing response, and adjunctive treatments.

Onset

Initial improvement in hydration and skin texture may be noticeable within days to weeks after treatment, with more visible scar remodeling and collagen-related benefits developing gradually over 4\u20138 weeks and continuing to improve with successive sessions.